Latest Insights,Two-peptide lantibiotics: a medical perspective

The persistent and growing threat of antibiotic resistance necessitates the exploration and development of novel antimicrobial agents. Among the most promising candidates are lantibiotics, a distinctive group of ribosomally synthesized, post-translationally modified antimicrobial peptides. While single-peptide lantibiotics have garnered attention, the focus of this article, from a medical perspective, is on two-peptide lantibiotics. These fascinating molecules, characterized by the synergistic action of their constituent peptides, offer a unique avenue for combating bacterial infections.

Understanding Two-Peptide Lantibiotics

At their core, lantibiotics are characterized by the presence of unusual amino acids, most notably lanthionine (Lan) and β-methyllanthionine (MeLan), which are formed through post-translational modifications of cysteine residues. These modifications create thioether bridges that confer structural rigidity and stability to the peptide backbone. The term "two-peptide lantibiotic" specifically refers to those that require the presence and coordinated action of two distinct mature peptides for their full antimicrobial efficacy. This synergistic interaction is a key feature that distinguishes them from single-peptide variants.

Research has highlighted several notable examples of two-peptide lantibiotics. Lacticin 3147, for instance, is a well-studied two-peptide lantibiotic that exhibits broad-spectrum activity against Gram-positive pathogens. Studies have demonstrated that the two peptides of lacticin 3147 work in concert, with optimal activity observed at a 1:1 stoichiometry, and its efficacy is comparable to that of the commercially used lantibiotic nisin. Another significant example is lichenicidin, a two-peptide lantibiotic identified to possess potent antimicrobial activity against a range of challenging bacteria, including *Listeria monocytogenes* and methicillin-resistant *Staphylococcus aureus* (MRSA). Furthermore, haloduracin is a two-peptide lantibiotic whose components display potent antimicrobial activity in a synergistic manner. More recently, Enterocin DD14 (EntDD14) has been identified as a leaderless two-peptide bacteriocin produced by *Enterococcus faecalis* 14.

Mechanism of Action: A Synergistic Assault

The precise mechanism of action for many two-peptide lantibiotics involves a multi-pronged attack on bacterial cells. While variations exist, a common theme is their ability to form pores in biological membranes, destabilize lipid packaging, and disrupt the peptidoglycan layer. The synergistic interaction between the two peptides is crucial for this process. For example, in the case of lacticin 3147, research has shown that its two-peptide lantibiotic lacticin 3147 acts synergistically with other agents, such as polymyxin, to inhibit bacterial growth.

The two mature peptides, such as Bliα and Bliβ in some systems, are necessary for full activity against target bacteria. This coordinated action allows for efficient binding to specific targets within the bacterial cell envelope, often involving lipid II, a precursor molecule essential for peptidoglycan synthesis. The formation of pores leads to leakage of essential cellular contents and ultimately cell death. This mechanism of action is distinct from many conventional antibiotics, making lantibiotics less prone to existing resistance mechanisms.

Medical Significance and Future Potential

The medical perspective on two-peptide lantibiotics is largely driven by their potent antimicrobial activity and their potential to overcome antibiotic resistance. Their ability to target Gram-positive bacteria, including many clinically significant pathogens, makes them valuable candidates for therapeutic development. The discovery of novel two-peptide lantibiotic compounds continues, with efforts focused on identifying agents with improved potency, broader spectrum of activity, and favorable pharmacokinetic properties.

Moreover, the research into two-peptide lantibiotics is not solely focused on discovery but also on bioengineering and optimization for therapeutic success. Studies have explored the production of two-peptide lantibiotics from various sources, including bacteria like *Bacillus licheniformis B-511*, which produces the lantibiotic lichenicidin. The potential for bioengineering lantibiotics opens up avenues for creating modified versions with enhanced therapeutic profiles.

The development of two-peptide lantibiotics as therapeutic agents is still in its early stages, but the evidence is compelling. The ability of these small microbial peptide antibiotics to exhibit significant activity, with some studies showing that both peptides protected greater than 80% of mice from infection-caused deaths, underscores their therapeutic promise. As our understanding of their structure, biosynthesis, and mode of action deepens, lantibiotics and particularly two-peptide lantibiotics are poised to play an increasingly important role in the fight against infectious diseases. Their unique mechanisms and the ongoing research into their applications represent a vital frontier in modern medicine.